Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of Malic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.50 |
| ▸ | TET3 | O43151 | 2/20 | 0.50 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 2/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malic Acid SCHEMBL29212744 | 0.93 | SMN1; SMN2 (0.65) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| Malic Acid SCHEMBL2547198 | 0.91 | SMN1; SMN2 (0.62) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| Malic Acid SCHEMBL409860 | 0.90 | SMN1; SMN2 (0.83) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| Oxaloacetate SCHEMBL19025323 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| Malic Acid SCHEMBL28541911 | 0.87 | SMN1; SMN2 (0.79) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| Malic Acid SCHEMBL9782806 | 0.87 | SMN1; SMN2 (0.88) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| Malic Acid SCHEMBL6863763 | 0.87 | SMN1; SMN2 (0.88) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| Malic Acid SCHEMBL856 | 0.87 | — | — | |
| Malic Acid SCHEMBL14125844 | 0.87 | SMN1; SMN2 (1.00) | SMN1; SMN2TET2TET3TET1SLC22A6 | |
| Malic Acid SCHEMBL89131 | 0.87 | SMN1; SMN2 (1.00) | SMN1; SMN2TET2TET3TET1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004082643-A2 | COSMETIC COMPOSITION | SHISEIDO INTERNATIONAL FRANCE (FR) | 2004-09-30 | — | — | WO | claimed |
| US-20240011056-A1 | 2,3-Butanediol Production, Methyl Ethyl Ketone Production, and Induction of Drought Tolerance in Plants | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-01-11 | — | — | US | disclosed |
| CN-111808900-B | Method for reducing NAD analogue by using formic acid | 中国科学院大连化学物理研究所 | 2023-06-20 | — | — | CN | disclosed |
| CN-109837321-B | Reduction method of NAD analogue | 中国科学院大连化学物理研究所（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-108430485-B | Anti-pollution compound containing oily extract and water extract of calendula officinalis and water extract of lily bulb and application of anti-pollution compound | MP2化妆品解决方案有限责任公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-111808900-A | Method for reducing NAD analogue by formic acid | 中国科学院大连化学物理研究所 | 2020-10-23 | — | — | CN | disclosed |
| US-10770276-B2 | Techniques of mass spectrometry for isotopomer analysis and related systems and methods | YALE UNIVERSITY (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200234938-A1 | TECHNIQUES OF MASS SPECTROMETRY FOR ISOTOPOMER ANALYSIS AND RELATED SYSTEMS AND METHODS | YALE UNIVERSITY (US) | 2020-07-23 | — | — | US | disclosed |
| US-10695285-B2 | Anti-pollution complex comprising calendula extracts and an aqueous extract of lilum candidum bulb and uses thereof | MP2 COSMETIC SOLUTIONS SARL (FR) | 2020-06-30 | — | — | US | disclosed |
| EP-3380201-B1 | ANTI-POLLUTION COMPLEX COMPRISING OILY AND AQUEOUS CALENDULA EXTRACTS AND AN AQUEOUS EXTRACT OF LILIUM CANDIDUM BULB AND USES THEREOF | MP2 COSMETIC SOLUTIONS SARL (FR) | 2020-02-19 | — | — | EP | disclosed |
| WO-2003077880-A1 | METHOD FOR THE PRODUCTION OF PHYTOALEXINS | ENNAMANY RACHID (FR) | 2003-09-25 | — | — | WO | disclosed |
| US-20030148533-A1 | Measurement of gluconeogenesis and intermediary metabolism using stable isotopes | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-08-07 | — | — | US | disclosed |
| US-20030013763-A1 | Glycerol-lactate esters for use as an energy supplement during exercise and recovery | BROOKS GEORGE A (US) | 2003-01-16 | — | — | US | disclosed |
| US-20030008838-A1 | Method of increasing endogenous leptin production | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| US-6482853-B1 | Lactate thiolester for cardiac energy resuscitation and prevention of reperfusion injury and use as an energy supplement during exercise and recovery | BROOKS GEORGE A (US) | 2002-11-19 | — | — | US | disclosed |
| WO-2002081751-A2 | A METHOD OF INCREASING ENDOGENOUS LEPTIN PRODUCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-10-17 | — | — | WO | disclosed |
| US-20020086006-A1 | Human mitochondrial malate dehydrogenase | INCYTE PHARMACEUTICALS, INC. | 2002-07-04 | — | — | US | disclosed |
| US-6274138-B1 | USED IN DIAGNOSIS, PREVENTION, AND TREATMENT OF DEVELOPMENTAL, VESICLE TRAFFICKING, IMMUNOLOGICAL, AND NEOPLASTIC DISORDERS | INCYTE GENOMICS, INC. | 2001-08-14 | — | — | US | disclosed |
| US-6013858-A | TRANSGENIC MOUSE WHOSE GENOME CONTAINS A DEFECTIVE ENDOGENOUS TRANSPORT PROTEIN INVOLVED IN OXIDATIVE PHOSPHORYLATION; A MODEL FOR TREATMENT AND STUDY OF MITOCHONDRIAL DISEASE AND MODULATORS OF MITOCHONDRIAL EXPRESSION | EMORY UNIVERSITY (US) | 2000-01-11 | — | — | US | disclosed |
| WO-1998019714-A1 | MOUSE LACKING HEART-MUSCLE ADENINE NUCLEOTIDE TRANSLOCATOR PROTEIN AND METHODS | EMORY UNIVERSITY (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013763-A1 | Glycerol-lactate esters for use as an energy supplement during exercise and recovery | GYS1, PYGM, GYS2 | SMN1; SMN2 1382/4885TET2 4567/4885TET3 3308/4885 |
| US-10695285-B2 | Anti-pollution complex comprising calendula extracts and an aqueous extract of lilum candidum bulb and uses thereof | LAGE3, POLR1C, NACA | SMN1; SMN2 4547/4885TET2 2570/4885TET3 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.